Level Bio Valuation

Is LEVBIO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LEVBIO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LEVBIO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LEVBIO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LEVBIO?

Key metric: As LEVBIO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LEVBIO. This is calculated by dividing LEVBIO's market cap by their current revenue.
What is LEVBIO's PS Ratio?
PS Ratio	0.9x
Sales	SEK 23.74m
Market Cap	SEK 19.02m

LEVBIO key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.7x
Enterprise Value/EBITDA	-1.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does LEVBIO's PS Ratio compare to its peers?

The above table shows the PS ratio for LEVBIO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.2x
PEXA B PExA	24.7x	n/a	SEK 19.7m
ATANA Attana	2.2x	n/a	SEK 10.3m
ISAB Inhalation Sciences Sweden	3.8x	59.5%	SEK 65.8m
AROC AroCell	2x	25.9%	SEK 101.8m
LEVBIO Level Bio	0.9x	n/a	SEK 19.0m

Price-To-Sales vs Peers: LEVBIO is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (8.2x).

Price to Sales Ratio vs Industry

How does LEVBIO's PS Ratio compare vs other companies in the European Life Sciences Industry?

5 Companies	Price / Sales	Estimated Growth	Market Cap

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: LEVBIO is good value based on its Price-To-Sales Ratio (0.9x) compared to the European Life Sciences industry average (4.2x).

Price to Sales Ratio vs Fair Ratio

What is LEVBIO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LEVBIO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.9x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LEVBIO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AstraZeneca

UK£156.0b

A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

AZN

UK£1,413.50

-1.8%

4.5%

Swedish Orphan Biovitrum

SEK 99.8b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 290.60

-12.4%

15.7%

PMD Device Solutions

SEK 33.2m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.28

-14.7%

n/a